Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease

Trial Details

NCT ID
NCT06055881
Phase
NA
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Biospecimen Collection
  • Surveys
  • Stereotactic Body Radiation Therapy (SBRT)
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Histological confirmation of primary breast cancer.
  • Patients with metastatic breast cancer and at least 12 months of clinical response to first-line systemic therapy, with the subsequent development …
  • NOTE: patients with de novo metastatic disease and those developed metastatic disease after initially localized disease can both be included.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →